Filing Summary
Business Context and Reporting Period
Rafael Holdings, Inc. filed this Form 8-K on September 30, 2026. The filing reports that its subsidiary, Cyclo Therapeutics, LLC, announced topline efficacy and safety data from the pivotal Phase 3 TransportNPC study (CTD-TCNPC-301) of Trappsol Cyclo, intravenous hydroxypropyl-β-cyclodextrin, in 94 patients with Niemann-Pick Disease Type C.
Financial Performance and Liquidity
This 8-K does not provide financial statements or data on revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Study Results
The filing identifies the release of topline study data as the material event, but the press release’s detailed results are not included in the supplied filing text. Efficacy and safety outcomes, statistical findings, and any adverse-event details are therefore not clear from the provided text.
Outlook, Risks, and Filing Status
The filing refers readers to forward-looking-statement cautions in the press release, which is not provided here. The information, including the press release, was furnished under Items 7.01 and 2.02 and is not deemed filed with the SEC unless expressly stated otherwise.
Investor Verification Points
- Review Exhibit 99.1 for the actual efficacy, safety, and statistical results from the 94-patient study.
- Verify any stated next steps, regulatory plans, timing, or limitations in the press release.
- Consult Rafael Holdings’ financial filings for current financial performance, cash position, and liquidity; this 8-K does not provide those figures.